|
Jul 25
|
scPharmaceuticals Announces Filing Acceptance of Supplemental New Drug Application (sNDA) Seeking to Expand FUROSCIX Indication to Include Chronic Kidney Disease
|
|
Jul 24
|
When Will scPharmaceuticals Inc. (NASDAQ:SCPH) Breakeven?
|
|
May 15
|
Q1 2024 scPharmaceuticals Inc Earnings Call
|
|
May 15
|
scPharmaceuticals Inc (SCPH) (Q1 2024) Earnings Call Transcript Highlights: Navigating ...
|
|
May 14
|
ScPharmaceuticals, Inc. (SCPH) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 14
|
scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
|
|
May 13
|
scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
|
|
May 7
|
scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024
|
|
Apr 24
|
scPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) Injection
|
|
Mar 27
|
Those who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 62%
|
|
Mar 16
|
scPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call Transcript
|
|
Mar 13
|
scPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX Growth
|
|
Mar 13
|
scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
|
|
Mar 6
|
scPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024
|
|
Nov 1
|
scPharmaceuticals to Announce Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
|
|
Aug 10
|
ScPharmaceuticals, Inc. (SCPH) Reports Q2 Loss, Tops Revenue Estimates
|
|
Aug 10
|
scPharmaceuticals Inc. Reports Second Quarter 2023 Financial Results and Provides Business Update
|